Literature DB >> 32195762

CORR Insights®: External Validation of PATHFx Version 3.0 in Patients Treated Surgically and Nonsurgically for Symptomatic Skeletal Metastases.

Adam S Levin1.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32195762      PMCID： PMC7282601          DOI： 10.1097/CORR.0000000000001148

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN： 0009-921X            Impact factor:   4.755


× No keyword cloud information.
  9 in total

1.  Survival in patients operated on for pathologic fracture: implications for end-of-life orthopedic care.

Authors:  Saminathan S Nathan; John H Healey; Danilo Mellano; Bang Hoang; Isobel Lewis; Carol D Morris; Edward A Athanasian; Patrick J Boland
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

2.  Can We Estimate Short- and Intermediate-term Survival in Patients Undergoing Surgery for Metastatic Bone Disease?

Authors:  Jonathan A Forsberg; Rikard Wedin; Patrick J Boland; John H Healey
Journal:  Clin Orthop Relat Res       Date:  2016-12-01       Impact factor: 4.176

3.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.

Authors:  Robert J Motzer; Nizar M Tannir; David F McDermott; Osvaldo Arén Frontera; Bohuslav Melichar; Toni K Choueiri; Elizabeth R Plimack; Philippe Barthélémy; Camillo Porta; Saby George; Thomas Powles; Frede Donskov; Victoria Neiman; Christian K Kollmannsberger; Pamela Salman; Howard Gurney; Robert Hawkins; Alain Ravaud; Marc-Oliver Grimm; Sergio Bracarda; Carlos H Barrios; Yoshihiko Tomita; Daniel Castellano; Brian I Rini; Allen C Chen; Sabeen Mekan; M Brent McHenry; Megan Wind-Rotolo; Justin Doan; Padmanee Sharma; Hans J Hammers; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-03-21       Impact factor: 91.245

4.  Can A Multivariate Model for Survival Estimation in Skeletal Metastases (PATHFx) Be Externally Validated Using Japanese Patients?

Authors:  Koichi Ogura; Tabu Gokita; Yusuke Shinoda; Hirotaka Kawano; Tatsuya Takagi; Keisuke Ae; Akira Kawai; Rikard Wedin; Jonathan A Forsberg
Journal:  Clin Orthop Relat Res       Date:  2017-05-30       Impact factor: 4.176

5.  Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Authors:  Leora Horn; David R Spigel; Everett E Vokes; Esther Holgado; Neal Ready; Martin Steins; Elena Poddubskaya; Hossein Borghaei; Enriqueta Felip; Luis Paz-Ares; Adam Pluzanski; Karen L Reckamp; Marco A Burgio; Martin Kohlhäeufl; David Waterhouse; Fabrice Barlesi; Scott Antonia; Oscar Arrieta; Jérôme Fayette; Lucio Crinò; Naiyer Rizvi; Martin Reck; Matthew D Hellmann; William J Geese; Ang Li; Anne Blackwood-Chirchir; Diane Healey; Julie Brahmer; Wilfried E E Eberhardt
Journal:  J Clin Oncol       Date:  2017-10-12       Impact factor: 44.544

6.  Estimating survival in patients with operable skeletal metastases: an application of a bayesian belief network.

Authors:  Jonathan Agner Forsberg; John Eberhardt; Patrick J Boland; Rikard Wedin; John H Healey
Journal:  PLoS One       Date:  2011-05-13       Impact factor: 3.240

7.  How do we estimate survival? External validation of a tool for survival estimation in patients with metastatic bone disease-decision analysis and comparison of three international patient populations.

Authors:  Andrea Piccioli; M Silvia Spinelli; Jonathan A Forsberg; Rikard Wedin; John H Healey; Vincenzo Ippolito; Primo Andrea Daolio; Pietro Ruggieri; Giulio Maccauro; Alessandro Gasbarrini; Roberto Biagini; Raimondo Piana; Flavio Fazioli; Alessandro Luzzati; Alberto Di Martino; Francesco Nicolosi; Francesco Camnasio; Michele Attilio Rosa; Domenico Andrea Campanacci; Vincenzo Denaro; Rodolfo Capanna
Journal:  BMC Cancer       Date:  2015-05-22       Impact factor: 4.430

8.  New prognostic factors and scoring system for patients with skeletal metastasis.

Authors:  Hirohisa Katagiri; Rieko Okada; Tatsuya Takagi; Mitsuru Takahashi; Hideki Murata; Hideyuki Harada; Tetsuo Nishimura; Hirofumi Asakura; Hirofumi Ogawa
Journal:  Cancer Med       Date:  2014-07-10       Impact factor: 4.452

9.  External Validation of PATHFx Version 3.0 in Patients Treated Surgically and Nonsurgically for Symptomatic Skeletal Metastases.

Authors:  Ashley B Anderson; Rikard Wedin; Nicola Fabbri; Patrick Boland; John Healey; Jonathan A Forsberg
Journal:  Clin Orthop Relat Res       Date:  2020-04       Impact factor: 4.755
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.